Revvity (RVTY)
Market Price (3/9/2026): $91.4 | Market Cap: $10.3 BilSector: Health Care | Industry: Health Care Equipment
Revvity (RVTY)
Market Price (3/9/2026): $91.4Market Cap: $10.3 BilSector: Health CareIndustry: Health Care Equipment
Investment Highlights Why It Matters Detailed financial logic regarding cash flow yields vs trend-riding momentum.
| Attractive cash flow generationCFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is 20%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is 18% | Weak multi-year price returns2Y Excs Rtn is -45%, 3Y Excs Rtn is -96% | Expensive valuation multiplesP/EBITPrice/EBIT or Price/(Operating Income) ratio is 29x, P/EPrice/Earnings or Price/(Net Income) is 43x |
| Low stock price volatilityVol 12M is 40% | Weak revenue growthRev Chg 3Y AvgRevenue Change % averaged over trailing 3 years is -4.4% | |
| Megatrend and thematic driversMegatrends include Biotechnology & Genomics, and Precision Medicine. Themes include Advanced Diagnostics, Personalized Diagnostics, Show more. |
| Attractive cash flow generationCFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is 20%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is 18% |
| Low stock price volatilityVol 12M is 40% |
| Megatrend and thematic driversMegatrends include Biotechnology & Genomics, and Precision Medicine. Themes include Advanced Diagnostics, Personalized Diagnostics, Show more. |
| Weak multi-year price returns2Y Excs Rtn is -45%, 3Y Excs Rtn is -96% |
| Expensive valuation multiplesP/EBITPrice/EBIT or Price/(Operating Income) ratio is 29x, P/EPrice/Earnings or Price/(Net Income) is 43x |
| Weak revenue growthRev Chg 3Y AvgRevenue Change % averaged over trailing 3 years is -4.4% |
Qualitative Assessment
AI Analysis | Feedback
1. Margin pressure and segment-specific challenges despite Q4 2025 earnings beat.
Revvity reported adjusted earnings per share of $1.70 and revenue of $772.06 million for Q4 2025, both exceeding analyst expectations. However, the adjusted operating margin declined 60 basis points year-over-year to 29.7%. More significantly, the Diagnostics segment's adjusted operating margins saw a larger decline of 230 basis points year-over-year to 23.4%, attributed to tariffs and product mix, while the Life Sciences segment continued to face challenging market conditions. This underlying profitability pressure, particularly in a key segment, tempered investor enthusiasm despite the headline beats, leading to an approximate 4.6% stock decline in pre-market trading on the earnings release day.
2. Conservative 2026 guidance amidst market skepticism regarding growth.
The company's full-year 2026 guidance included an anticipated adjusted EPS of $5.35 to $5.45, representing approximately 6-8% growth over 2025, and projected revenue of roughly $3 billion with 2-3% organic growth. While the EPS guidance slightly beat analyst estimates at the midpoint, the modest organic revenue growth outlook, coupled with overall market skepticism about Revvity's long-term growth potential and margin expansion, contributed to a cautious investor sentiment.
Show more
Stock Movement Drivers
Fundamental Drivers
The -12.5% change in RVTY stock from 11/30/2025 to 3/8/2026 was primarily driven by a -15.5% change in the company's P/E Multiple.| (LTM values as of) | 11302025 | 3082026 | Change |
|---|---|---|---|
| Stock Price ($) | 104.35 | 91.34 | -12.5% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 2,813 | 2,856 | 1.5% |
| Net Income Margin (%) | 8.4% | 8.4% | 0.0% |
| P/E Multiple | 50.7 | 42.8 | -15.5% |
| Shares Outstanding (Mil) | 115 | 113 | 2.0% |
| Cumulative Contribution | -12.5% |
Market Drivers
11/30/2025 to 3/8/2026| Return | Correlation | |
|---|---|---|
| RVTY | -12.5% | |
| Market (SPY) | -1.6% | 51.7% |
| Sector (XLV) | -3.1% | 31.2% |
Fundamental Drivers
The 1.5% change in RVTY stock from 8/31/2025 to 3/8/2026 was primarily driven by a 15.5% change in the company's P/E Multiple.| (LTM values as of) | 8312025 | 3082026 | Change |
|---|---|---|---|
| Stock Price ($) | 89.99 | 91.34 | 1.5% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 2,798 | 2,856 | 2.1% |
| Net Income Margin (%) | 10.2% | 8.4% | -17.1% |
| P/E Multiple | 37.1 | 42.8 | 15.5% |
| Shares Outstanding (Mil) | 118 | 113 | 3.9% |
| Cumulative Contribution | 1.5% |
Market Drivers
8/31/2025 to 3/8/2026| Return | Correlation | |
|---|---|---|
| RVTY | 1.5% | |
| Market (SPY) | 4.5% | 48.4% |
| Sector (XLV) | 11.6% | 48.0% |
Fundamental Drivers
The -18.3% change in RVTY stock from 2/28/2025 to 3/8/2026 was primarily driven by a -14.7% change in the company's P/E Multiple.| (LTM values as of) | 2282025 | 3082026 | Change |
|---|---|---|---|
| Stock Price ($) | 111.83 | 91.34 | -18.3% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 2,755 | 2,856 | 3.7% |
| Net Income Margin (%) | 9.8% | 8.4% | -13.9% |
| P/E Multiple | 50.2 | 42.8 | -14.7% |
| Shares Outstanding (Mil) | 121 | 113 | 7.4% |
| Cumulative Contribution | -18.3% |
Market Drivers
2/28/2025 to 3/8/2026| Return | Correlation | |
|---|---|---|
| RVTY | -18.3% | |
| Market (SPY) | 14.2% | 58.0% |
| Sector (XLV) | 3.9% | 61.8% |
Fundamental Drivers
The -26.1% change in RVTY stock from 2/28/2023 to 3/8/2026 was primarily driven by a -51.9% change in the company's Net Income Margin (%).| (LTM values as of) | 2282023 | 3082026 | Change |
|---|---|---|---|
| Stock Price ($) | 123.61 | 91.34 | -26.1% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 3,599 | 2,856 | -20.6% |
| Net Income Margin (%) | 17.6% | 8.4% | -51.9% |
| P/E Multiple | 24.7 | 42.8 | 73.5% |
| Shares Outstanding (Mil) | 126 | 113 | 11.5% |
| Cumulative Contribution | -26.1% |
Market Drivers
2/28/2023 to 3/8/2026| Return | Correlation | |
|---|---|---|
| RVTY | -26.1% | |
| Market (SPY) | 76.0% | 46.6% |
| Sector (XLV) | 25.7% | 52.5% |
Price Returns Compared
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | Total [1] | |
|---|---|---|---|---|---|---|---|
| Returns | |||||||
| RVTY Return | 40% | -30% | -22% | 2% | -13% | -0% | -32% |
| Peers Return | 32% | -27% | -13% | -1% | 1% | -9% | -23% |
| S&P 500 Return | 27% | -19% | 24% | 23% | 16% | -0% | 82% |
Monthly Win Rates [3] | |||||||
| RVTY Win Rate | 83% | 50% | 42% | 33% | 42% | 33% | |
| Peers Win Rate | 73% | 37% | 48% | 47% | 50% | 13% | |
| S&P 500 Win Rate | 75% | 42% | 67% | 75% | 67% | 33% | |
Max Drawdowns [4] | |||||||
| RVTY Max Drawdown | -16% | -42% | -41% | -9% | -26% | -2% | |
| Peers Max Drawdown | -5% | -38% | -33% | -13% | -31% | -13% | |
| S&P 500 Max Drawdown | -1% | -25% | -1% | -2% | -15% | -1% | |
[1] Cumulative total returns since the beginning of 2021
[2] Peers: TMO, DHR, A, BIO, ILMN.
[3] Win Rate = % of calendar months in which monthly returns were positive
[4] Max drawdown represents maximum peak-to-trough decline within a year
[5] 2026 data is for the year up to 3/6/2026 (YTD)
How Low Can It Go
| Event | RVTY | S&P 500 |
|---|---|---|
| 2022 Inflation Shock | ||
| % Loss | -59.2% | -25.4% |
| % Gain to Breakeven | 145.0% | 34.1% |
| Time to Breakeven | Not Fully Recovered days | 464 days |
| 2020 Covid Pandemic | ||
| % Loss | -34.4% | -33.9% |
| % Gain to Breakeven | 52.5% | 51.3% |
| Time to Breakeven | 77 days | 148 days |
| 2018 Correction | ||
| % Loss | -26.1% | -19.8% |
| % Gain to Breakeven | 35.3% | 24.7% |
| Time to Breakeven | 87 days | 120 days |
| 2008 Global Financial Crisis | ||
| % Loss | -63.0% | -56.8% |
| % Gain to Breakeven | 169.9% | 131.3% |
| Time to Breakeven | 1,285 days | 1,480 days |
Compare to TMO, DHR, A, BIO, ILMN
In The Past
Revvity's stock fell -59.2% during the 2022 Inflation Shock from a high on 12/31/2021. A -59.2% loss requires a 145.0% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
About Revvity (RVTY)
AI Analysis | Feedback
Revvity is like Thermo Fisher Scientific for specialized life science and diagnostic solutions.
Revvity is similar to Agilent Technologies for advanced scientific instruments and diagnostic tools.
AI Analysis | Feedback
- Life Sciences Research Instruments & Reagents: Provides specialized laboratory instruments, reagents, and consumables used in drug discovery, genomics, cell biology, and other advanced research applications.
- Diagnostic Solutions: Offers a range of products and services for disease detection, including newborn screening, prenatal testing, and infectious disease diagnostics.
- Informatics Software & Services: Delivers software platforms and data analytics solutions to manage, analyze, and interpret complex biological and clinical data.
AI Analysis | Feedback
Revvity (symbol: RVTY) primarily sells its products and services to other companies and institutions, making it a business-to-business (B2B) company.
Revvity does not publicly disclose the names of specific major customers in its financial reports or other public statements. This is common for companies like Revvity, which serve a broad and diverse customer base across multiple segments globally. Instead of individual company names, their customer base can be described by the following major categories of organizations they serve:
- Pharmaceutical and Biotechnology Companies: These companies are major customers, utilizing Revvity's life science research tools, reagents, software, and services for drug discovery, development, and manufacturing processes. This category includes a vast number of public and private companies globally.
- Academic and Government Research Institutions: Universities, research hospitals, and government laboratories (such as those funded by organizations like the National Institutes of Health (NIH)) are significant customers, relying on Revvity's solutions for fundamental and applied scientific research. These are typically not public companies.
- Clinical Diagnostic Laboratories and Healthcare Providers: Revvity's diagnostic products, used for areas like reproductive health, infectious disease testing, and applied genomics, are sold to clinical laboratories, hospitals, and other healthcare providers. This category includes both large public laboratory networks and smaller private entities.
- Food, Environmental, and Industrial Markets: This segment encompasses companies and laboratories in various industries that require analytical solutions for quality control, safety testing, and compliance. Examples include food and beverage manufacturers, environmental testing firms, and industrial research and quality control labs. This category includes a mix of public and private companies.
AI Analysis | Feedback
nullAI Analysis | Feedback
Prahlad Singh President and Chief Executive Officer
Prahlad Singh was appointed President and Chief Executive Officer of Revvity (formerly PerkinElmer) in December 2019, having joined the company in May 2014 as President of the Diagnostics business. He led the company through a significant transformation, including navigating the COVID-19 pandemic and overseeing its portfolio evolution. Notably, he was at the helm when the company completed the divestiture of its Applied, Food and Enterprise Services businesses to New Mountain Capital, a transaction that resulted in the creation of Revvity. Prior to Revvity, he served as General Manager of GE Healthcare's Women's Health business from 2012 to 2014. His career also includes senior executive roles in strategy, business development, and mergers and acquisitions at both GE Healthcare and Philips Healthcare. Earlier, from 1995 to 2007, he held leadership positions at DuPont Pharmaceuticals and Bristol-Myers Squibb Medical Imaging. Dr. Singh holds a PhD in chemistry from the University of Missouri-Columbia and an MBA from Northeastern University.
Max Krakowiak Senior Vice President and Chief Financial Officer
Max Krakowiak serves as the Senior Vice President and Chief Financial Officer at Revvity, a role he assumed in 2023, following his appointment as CFO of PerkinElmer in August 2022. He has been a key member of Revvity's finance leadership team since 2018. Before his current position, he was the Vice President of Corporate Finance, overseeing financial planning and analysis, as well as commercial and business development finance. Krakowiak spent seven years at GE, most recently as a member of the executive leadership team in the company's corporate audit staff, where he oversaw teams responsible for corporate strategy, external investigations, and investor relations across global operating segments. He is also an alumnus of the GE Financial Management leadership program. Additionally, he had a brief career as a minor league baseball player for the Seattle Mariners organization. Krakowiak earned a bachelor's degree in finance from Fordham University.
Joel Goldberg Senior Vice President, Administration, General Counsel and Secretary
Joel Goldberg holds the position of Senior Vice President, Administration, General Counsel and Secretary at Revvity. In this role, he provides expert insights and strategic guidance on a range of legal, regulatory, and policy matters affecting the company. He leads dedicated teams focused on providing collaborative support and guidance across various corporate issues and business functions.
Magali Four Senior Vice President, Chief People and Culture Officer
Magali Four is the Senior Vice President, Chief People and Culture Officer at Revvity. (Detailed background information was not available in the provided search results.)
Tajinder Vohra Senior Vice President of Global Operations
Tajinder Vohra serves as the Senior Vice President of Global Operations at Revvity, a role he has held since 2015. He is responsible for overseeing the company's manufacturing, supply chain, customer care, and distribution functions. With nearly 30 years of experience in operations management, he leads a global team that collaborates closely with R&D and Product Management to facilitate the launch and manufacturing of products across Revvity's Life Sciences and Diagnostics businesses.
AI Analysis | Feedback
nullAI Analysis | Feedback
The rapid acceleration and adoption of artificial intelligence (AI), machine learning (ML), and advanced computational biology platforms represent an emerging threat. These technologies are increasingly capable of dramatically accelerating drug discovery, target identification, and diagnostic insights with potentially reduced reliance on traditional, iterative wet lab experimentation that underpins demand for Revvity's specialized laboratory instruments and reagents. As AI-driven solutions become more predictive and efficient, they could lead to a fundamental shift in research and diagnostic paradigms, potentially commoditizing certain physical lab tools or reducing the overall volume of specialized reagent consumption by making discovery more computationally intensive. Additionally, the rise of cloud-native, integrated data platforms and open-source lab automation solutions offers alternatives to Revvity's proprietary ecosystems, enabling labs to build more flexible, vendor-agnostic infrastructures that could diminish the value proposition of tightly bundled, proprietary offerings.
AI Analysis | Feedback
Revvity (symbol: RVTY) operates in significant global markets for its life sciences and diagnostics products and services. The company's estimated total addressable market (TAM) globally exceeds $60 billion.
More specifically, Revvity is a key player in several large and growing segments:
- Genomics Market: The global genomics market was valued at approximately US$42.6 billion in 2024 and is projected to reach US$66.8 billion by 2029.
- Proteomics Market: The global proteomics market was valued at approximately US$33.64 billion in 2024 and is projected to reach US$60.36 billion by 2029. Other estimates place the global proteomics market size at $32.8 billion in 2023, with a projection to reach $161.9 billion by 2035, or $24.2 billion in 2023, projected to reach $73.9 billion by 2032.
- Molecular Cytogenetics Market: The global molecular cytogenetics market size is estimated at USD 2.86 billion in 2025 and is projected to grow to approximately USD 7.82 billion by 2034. For the U.S. specifically, this market is valued at USD 962.90 million in 2025 and is projected to reach around USD 2,650.16 million by 2034.
AI Analysis | Feedback
Expected Drivers of Future Revenue Growth for Revvity (RVTY)
Revvity (NYSE: RVTY) is anticipated to drive future revenue growth over the next 2-3 years through several key areas, as indicated by recent earnings calls and analyst commentary:
- Continued Strength in the Diagnostics Segment: The Diagnostics business is consistently highlighted as a strong performer, with specific mentions of robust growth in reproductive health and immunodiagnostics. This segment "continues to do very well" and led growth with a 3% revenue increase in Q3 2025. The specialty diagnostic businesses have "strong and durable underlying market growth drivers that are more immune to changes in the macroeconomic environment".
- Expansion of the Software Business, particularly the Signals Software Franchise: Revvity's software business has demonstrated strong performance. The "Signals software franchise" exhibited approximately 30% organic growth in Q2 2025, contributing significantly to the Life Sciences segment's organic growth.
- Launch of New Products, including AI-driven Solutions, and Strategic Partnerships: The company's President and CEO, Prahlad Singh, emphasized that "key new product launches and strategic partnership initiatives" are coming to fruition and positioning the company for greater success in 2026 and beyond. AI-driven product launches have also been specifically highlighted as growth drivers.
- Recovery in Broader Industry Demand and Customer Activity: While the instrumentation business has faced challenges, management has noted a "path to recovery" and "improving signs of customer activity". The company is "positioned well to have a strong finish to the year with positive momentum as we head into 2026," contingent on sustained improvements in broader industry demand trends.
- Growth in the Reagents Business within Life Sciences: Despite declines in the instrumentation aspect of the Life Sciences segment, the reagents business has shown "solid growth". This indicates a resilient component within the Life Sciences portfolio that is expected to contribute to overall revenue.
AI Analysis | Feedback
Share Repurchases
- In October 2024, Revvity's Board of Directors authorized a new two-year $1 billion share repurchase program, which superseded a prior program announced in May 2023.
- Under the buyback program announced in November 2024, Revvity had repurchased shares totaling $627.06 million as of August 5, 2025.
- During the three months ended September 29, 2024, the company repurchased $153.4 million in common stock.
Share Issuance
- Revvity issued 14,339 shares of common stock in fiscal year 2024 under its Employee Stock Purchase Plan at a weighted-average price of $99.62 per share.
- In fiscal year 2023, 28,899 shares were issued at a weighted-average price of $108.37 per share through the Employee Stock Purchase Plan.
- For fiscal year 2022, 30,818 shares were issued under the Employee Stock Purchase Plan at a weighted-average price of $134.05 per share.
Outbound Investments
- In 2021, Revvity (operating as PerkinElmer at the time) acquired BioLegend, a global provider of life science antibodies and reagents, for $5.7 billion (net of cash acquired).
- Also in 2021, the company acquired Nexcelom and Oxford Immunotec for an aggregate of $1.2 billion, aiming to enhance its Life Sciences and Diagnostics segments.
Capital Expenditures
- Revvity reported capital expenditures of $86.6 million for fiscal year 2024, an increase from $81.4 million in fiscal year 2023.
- The company anticipates an increase in capital expenditures for fiscal year 2025, driven by a strategic focus on enhancing digital capabilities, product innovations, and realigning production infrastructure.
- Capital expenditure remains a pressured area, with a focus on regional manufacturing and investments in differentiated specialty diagnostics.
Latest Trefis Analyses
Trade Ideas
Select ideas related to RVTY.
| Date | Ticker | Company | Category | Trade Strategy | 6M Fwd Rtn | 12M Fwd Rtn | 12M Max DD |
|---|---|---|---|---|---|---|---|
| 02282026 | QDEL | QuidelOrtho | Insider | Insider Buys 45DStrong Insider BuyingCompanies with multiple insider buys in the last 45 days | 0.0% | 0.0% | 0.0% |
| 02272026 | CHE | Chemed | Dip Buy | DB | FCFY OPMDip Buy with High FCF Yield and High MarginBuying dips for companies with high FCF yield and meaningfully high operating margin | 0.0% | 0.0% | 0.0% |
| 02272026 | LLY | Eli Lilly | Monopoly | MY | Getting CheaperMonopoly-Like with P/S DeclineLarge cap with monopoly-like margins or cash flow generation and getting cheaper based on P/S multiple | 0.0% | 0.0% | 0.0% |
| 02202026 | HAE | Haemonetics | Dip Buy | DB | FCFY OPMDip Buy with High FCF Yield and High MarginBuying dips for companies with high FCF yield and meaningfully high operating margin | 3.5% | 3.5% | 0.0% |
| 02132026 | IQV | IQVIA | Dip Buy | DB | P/E OPMDip Buy with Low PE and High MarginBuying dips for companies with tame PE and meaningfully high operating margin | 7.1% | 7.1% | -3.0% |
| 09122025 | RVTY | Revvity | Dip Buy | DB | FCFY OPMDip Buy with High FCF Yield and High MarginBuying dips for companies with high FCF yield and meaningfully high operating margin | 18.8% | 18.8% | 0.0% |
Research & Analysis
Invest in Strategies
Wealth Management
Peer Comparisons
| Peers to compare with: |
Financials
| Median | |
|---|---|
| Name | |
| Mkt Price | 160.06 |
| Mkt Cap | 25.8 |
| Rev LTM | 5,704 |
| Op Inc LTM | 1,136 |
| FCF LTM | 962 |
| FCF 3Y Avg | 980 |
| CFO LTM | 1,238 |
| CFO 3Y Avg | 1,241 |
Growth & Margins
| Median | |
|---|---|
| Name | |
| Rev Chg LTM | 3.3% |
| Rev Chg 3Y Avg | -2.1% |
| Rev Chg Q | 5.4% |
| QoQ Delta Rev Chg LTM | 1.4% |
| Op Mgn LTM | 18.5% |
| Op Mgn 3Y Avg | 14.9% |
| QoQ Delta Op Mgn LTM | -0.2% |
| CFO/Rev LTM | 20.5% |
| CFO/Rev 3Y Avg | 18.7% |
| FCF/Rev LTM | 16.2% |
| FCF/Rev 3Y Avg | 15.2% |
Valuation
| Median | |
|---|---|
| Name | |
| Mkt Cap | 25.8 |
| P/S | 4.3 |
| P/EBIT | 21.3 |
| P/E | 26.6 |
| P/CFO | 19.6 |
| Total Yield | 4.0% |
| Dividend Yield | 0.0% |
| FCF Yield 3Y Avg | 3.3% |
| D/E | 0.2 |
| Net D/E | 0.1 |
Returns
| Median | |
|---|---|
| Name | |
| 1M Rtn | -9.9% |
| 3M Rtn | -12.9% |
| 6M Rtn | 0.0% |
| 12M Rtn | -6.2% |
| 3Y Rtn | -20.4% |
| 1M Excs Rtn | -9.4% |
| 3M Excs Rtn | -12.3% |
| 6M Excs Rtn | -3.0% |
| 12M Excs Rtn | -20.6% |
| 3Y Excs Rtn | -90.5% |
Segment Financials
Revenue by Segment| $ Mil | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Life Sciences | 1,399 | 1,292 | 1,293 | 898 | 1,716 |
| Diagnostics | 1,356 | 1,458 | 2,020 | 2,933 | 2,067 |
| Revenue purchase accounting adjustments | -1 | -3 | |||
| Total | 2,755 | 2,751 | 3,312 | 3,828 | 3,783 |
| $ Mil | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Life Sciences | 467 | 489 | 503 | 282 | 183 |
| Diagnostics | 354 | 320 | 782 | 1,433 | 874 |
| Purchase accounting adjustments | 0 | -5 | -46 | -41 | |
| Significant environmental matters | 0 | -2 | 0 | ||
| Transformation costs | 0 | ||||
| Significant litigation matters and settlements | -8 | -0 | 1 | ||
| Restructuring and other, net | -17 | -27 | -14 | -18 | |
| Asset impairment | -23 | 0 | 0 | ||
| Acquisition and divestiture-related costs | -25 | -69 | -40 | -63 | |
| Corporate expenses | -42 | -40 | -73 | -77 | -79 |
| Amortization of intangible assets | -359 | -365 | -371 | -257 | |
| Total | 347 | 301 | 743 | 1,258 | 979 |
Price Behavior
| Market Price | $91.34 | |
| Market Cap ($ Bil) | 10.3 | |
| First Trading Date | 12/29/2006 | |
| Distance from 52W High | -22.5% | |
| 50 Days | 200 Days | |
| DMA Price | $102.88 | $95.60 |
| DMA Trend | up | up |
| Distance from DMA | -11.2% | -4.5% |
| 3M | 1YR | |
| Volatility | 39.5% | 39.9% |
| Downside Capture | 203.91 | 164.97 |
| Upside Capture | 167.47 | 112.05 |
| Correlation (SPY) | 48.3% | 58.1% |
| 1M | 2M | 3M | 6M | 1Y | 3Y | |
|---|---|---|---|---|---|---|
| Beta | 1.88 | 1.74 | 1.71 | 1.49 | 1.18 | 1.03 |
| Up Beta | 1.08 | 1.61 | 1.98 | 1.94 | 1.16 | 0.95 |
| Down Beta | 3.90 | 1.69 | 1.42 | 1.20 | 0.99 | 1.00 |
| Up Capture | 81% | 200% | 165% | 164% | 129% | 74% |
| Bmk +ve Days | 9 | 20 | 31 | 70 | 142 | 431 |
| Stock +ve Days | 11 | 21 | 28 | 59 | 121 | 367 |
| Down Capture | 224% | 167% | 187% | 141% | 128% | 106% |
| Bmk -ve Days | 12 | 21 | 30 | 54 | 109 | 320 |
| Stock -ve Days | 10 | 20 | 33 | 65 | 130 | 384 |
[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
Based On 1-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with RVTY | |
|---|---|---|---|---|
| RVTY | -18.1% | 39.9% | -0.41 | - |
| Sector ETF (XLV) | 3.4% | 17.5% | 0.04 | 61.8% |
| Equity (SPY) | 16.4% | 19.2% | 0.66 | 57.8% |
| Gold (GLD) | 77.1% | 26.1% | 2.17 | -1.2% |
| Commodities (DBC) | 19.6% | 17.1% | 0.89 | 16.0% |
| Real Estate (VNQ) | 3.1% | 16.6% | 0.01 | 54.5% |
| Bitcoin (BTCUSD) | -24.9% | 45.6% | -0.49 | 30.0% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 5-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with RVTY | |
|---|---|---|---|---|
| RVTY | -6.2% | 33.3% | -0.13 | - |
| Sector ETF (XLV) | 7.6% | 14.5% | 0.34 | 56.7% |
| Equity (SPY) | 13.0% | 17.0% | 0.60 | 53.1% |
| Gold (GLD) | 24.2% | 17.2% | 1.14 | 10.8% |
| Commodities (DBC) | 11.9% | 19.0% | 0.51 | 9.0% |
| Real Estate (VNQ) | 5.0% | 18.8% | 0.17 | 49.9% |
| Bitcoin (BTCUSD) | 6.5% | 56.8% | 0.34 | 22.4% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 10-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with RVTY | |
|---|---|---|---|---|
| RVTY | 7.2% | 30.2% | 0.29 | - |
| Sector ETF (XLV) | 10.4% | 16.5% | 0.52 | 59.5% |
| Equity (SPY) | 15.0% | 17.9% | 0.72 | 57.8% |
| Gold (GLD) | 15.1% | 15.6% | 0.80 | 8.0% |
| Commodities (DBC) | 9.0% | 17.6% | 0.43 | 15.9% |
| Real Estate (VNQ) | 6.1% | 20.7% | 0.26 | 44.3% |
| Bitcoin (BTCUSD) | 65.9% | 66.8% | 1.05 | 14.4% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Earnings Returns History
Expand for More| Forward Returns | |||
|---|---|---|---|
| Earnings Date | 1D Returns | 5D Returns | 21D Returns |
| 2/2/2026 | -1.6% | -6.6% | -11.8% |
| 10/27/2025 | -1.7% | -5.4% | 1.7% |
| 7/28/2025 | -8.3% | -14.9% | -11.1% |
| 4/28/2025 | 0.8% | -0.3% | -2.2% |
| 1/31/2025 | -0.6% | -6.1% | -13.0% |
| 11/4/2024 | 3.1% | 1.2% | -5.0% |
| 7/29/2024 | 9.1% | 7.1% | 5.2% |
| 4/29/2024 | 3.5% | -0.9% | 10.2% |
| ... | |||
| SUMMARY STATS | |||
| # Positive | 11 | 7 | 11 |
| # Negative | 13 | 17 | 13 |
| Median Positive | 3.5% | 6.9% | 5.2% |
| Median Negative | -1.7% | -5.1% | -8.8% |
| Max Positive | 9.1% | 10.9% | 19.1% |
| Max Negative | -16.1% | -14.9% | -13.0% |
SEC Filings
Expand for More| Report Date | Filing Date | Filing |
|---|---|---|
| 12/31/2025 | 02/24/2026 | 10-K |
| 09/30/2025 | 11/04/2025 | 10-Q |
| 06/30/2025 | 08/05/2025 | 10-Q |
| 03/31/2025 | 05/06/2025 | 10-Q |
| 12/31/2024 | 02/25/2025 | 10-K |
| 09/30/2024 | 11/06/2024 | 10-Q |
| 06/30/2024 | 08/06/2024 | 10-Q |
| 03/31/2024 | 05/07/2024 | 10-Q |
| 12/31/2023 | 02/27/2024 | 10-K |
| 09/30/2023 | 11/07/2023 | 10-Q |
| 06/30/2023 | 08/09/2023 | 10-Q |
| 03/31/2023 | 05/12/2023 | 10-Q |
| 12/31/2022 | 03/01/2023 | 10-K |
| 09/30/2022 | 11/14/2022 | 10-Q |
| 06/30/2022 | 08/09/2022 | 10-Q |
| 03/31/2022 | 05/10/2022 | 10-Q |
Insider Activity
Expand for More| # | Owner | Title | Holding | Action | Filing Date | Price | Shares | Transacted Value | Value of Held Shares | Form |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Michas, Alexis P | The Cayre and Alexis Michas Foundation Corp. | Sell | 8282025 | 89.01 | 500 | 44,505 | 647,103 | Form | |
| 2 | McMurry-Heath, Michelle | Direct | Sell | 5302025 | 92.17 | 600 | 55,299 | 445,433 | Form | |
| 3 | McMurry-Heath, Michelle | Direct | Sell | 2072025 | 119.49 | 1,970 | 235,395 | 360,979 | Form | |
| 4 | Goldberg, Joel S | Please See Remarks | Direct | Sell | 1312025 | 126.73 | 15,170 | 1,922,513 | 4,232,823 | Form |
| 5 | Vohra, Tajinder S | Please See Remarks | Direct | Sell | 2042026 | 104.50 | 5,756 | 601,502 | 1,091,189 | Form |
External Quote Links
| Y Finance | Barrons |
| TradingView | Morningstar |
| SeekingAlpha | ValueLine |
| Motley Fool | Robinhood |
| CNBC | Etrade |
| MarketWatch | Unusual Whales |
| YCharts | Perplexity Finance |
| FinViz |
Prefer one of these to Trefis? Tell us why.